# Treatment of Adenocarcinoma of the Rectum With Transanal Local Excision for Complete Responders

> **NCT03941366** · NA · UNKNOWN · sponsor: **Henry Ford Health System** · enrollment: 15 (estimated)

## Conditions studied

- Rectal Cancer

## Interventions

- **PROCEDURE:** Standard of care chemotherapy with the change for avoidance of extensive surgery

## Key facts

- **NCT ID:** NCT03941366
- **Lead sponsor:** Henry Ford Health System
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-02-26
- **Primary completion:** 2025-01-01
- **Final completion:** 2025-01-01
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2023-01-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03941366

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03941366, "Treatment of Adenocarcinoma of the Rectum With Transanal Local Excision for Complete Responders". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03941366. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*